Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate
Open Access
- 29 April 2003
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 88 (9) , 1339-1345
- https://doi.org/10.1038/sj.bjc.6600916
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors.2002
- Angiogenesis as a predictor of long-term survival for 377 Japanese patients with breast cancerBreast Cancer Research and Treatment, 2001
- Primary Chemotherapy in Breast CancerAmerican Journal of Clinical Oncology, 1998
- Prospects with docetaxel in the treatment of patients with breast cancerEuropean Journal Of Cancer, 1997
- Current status of Taxotere® (docetaxel) as a new treatment in breast cancerBreast Cancer Research and Treatment, 1995
- Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6European Journal Of Cancer, 1994
- Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cmCancer, 1994
- Inflammatory Breast CancerAmerican Journal of Clinical Oncology, 1993
- Neoadjuvant chemotherapy in operable breast cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- Reporting results of cancer treatmentCancer, 1981